IL1A and COVID-19: Although anakinra, a monoclonal antibody directed against IL-1 receptor, has shown effectiveness in treating some forms of secondary haemophagocytic syndrome in pediatric patients [71], both anakinra and canakinumab, a monoclonal antibody directed against the ß subunit of IL-1, resulted in being safe but ineffective for the treatment of COVID-19 in a meta-analysis carried out on 16 RCTs [72].